Evaluation of SARS-CoV-2 Serological Testing in Patients with Multiple Myeloma and Other Hematologic Malignancies on Monoclonal Antibody Therapies.
COVID-19
M-spike
SARS-CoV-2
cross-reactivity
hematological malignancy
multiple myeloma
serology
therapeutic monoclonal antibodies
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
24 Nov 2020
24 Nov 2020
Historique:
received:
04
11
2020
revised:
19
11
2020
accepted:
20
11
2020
entrez:
1
12
2020
pubmed:
2
12
2020
medline:
2
12
2020
Statut:
epublish
Résumé
Patients with hematological malignancies (HM), including multiple myeloma (MM), frequently suffer from immune deficiency-associated infectious complications because of both the disease and the treatment. Alarming results from China and the UK confirm the vulnerability of HM patients to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection-driven coronavirus disease 2019 (COVID-19). Given that the immunoassay interference from the endogenous monoclonal immunoglobulin (M paraprotein) and treatment antibodies continually challenges the MM management, it is critical to evaluate the SARS-CoV-2 serology tests for suspected interference/cross-reactivity. We compared the degree of interference in three SARS-CoV-2 serology assay platforms in HM patients with and without COVID-19 and on various therapeutic monoclonal antibody (t-mAb) treatments. Further, we confirmed the cross-reactivity in pooled samples from normal and COVID-19 + samples spiked with respective antibodies in vitro. None of the 93 HM patient samples with or without t-MAbs showed cross-reactivity on any of the three serology platforms tested. The tested three serologic assays for SARS-CoV-2 are specific and do not have cross-reactivity with M-components or t-MAbs indicating that they can be used safely in oncology practice and in research exploring the immunologic response to COVID-19 in patients with HM.
Sections du résumé
BACKGROUND
BACKGROUND
Patients with hematological malignancies (HM), including multiple myeloma (MM), frequently suffer from immune deficiency-associated infectious complications because of both the disease and the treatment. Alarming results from China and the UK confirm the vulnerability of HM patients to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection-driven coronavirus disease 2019 (COVID-19). Given that the immunoassay interference from the endogenous monoclonal immunoglobulin (M paraprotein) and treatment antibodies continually challenges the MM management, it is critical to evaluate the SARS-CoV-2 serology tests for suspected interference/cross-reactivity.
METHODS
METHODS
We compared the degree of interference in three SARS-CoV-2 serology assay platforms in HM patients with and without COVID-19 and on various therapeutic monoclonal antibody (t-mAb) treatments. Further, we confirmed the cross-reactivity in pooled samples from normal and COVID-19 + samples spiked with respective antibodies in vitro.
RESULTS
RESULTS
None of the 93 HM patient samples with or without t-MAbs showed cross-reactivity on any of the three serology platforms tested.
CONCLUSIONS
CONCLUSIONS
The tested three serologic assays for SARS-CoV-2 are specific and do not have cross-reactivity with M-components or t-MAbs indicating that they can be used safely in oncology practice and in research exploring the immunologic response to COVID-19 in patients with HM.
Identifiants
pubmed: 33255154
pii: diagnostics10120992
doi: 10.3390/diagnostics10120992
pmc: PMC7760559
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Cancer Treat Res. 2016;169:207-225
pubmed: 27696265
Pathology. 2010;42(5):397-401
pubmed: 20632813
Lancet. 2020 Jun 20;395(10241):1919-1926
pubmed: 32473682
Br J Haematol. 2020 Jul;190(2):e83-e86
pubmed: 32438482
J Hematol Oncol. 2020 Jul 14;13(1):94
pubmed: 32664919
Br J Haematol. 2020 Jul;190(2):e64-e67
pubmed: 32420609
Acad Emerg Med. 2020 Aug;27(8):764-766
pubmed: 32492760
Leukemia. 2020 Jun;34(6):1637-1645
pubmed: 32332856
Clin Cancer Res. 2016 Nov 15;22(22):5453-5460
pubmed: 28151713
Clin Chem Lab Med. 2016 Jun 1;54(6):1085-93
pubmed: 26812875
Nat Med. 2020 Jun;26(6):845-848
pubmed: 32350462
Haematologica. 2015 Jan;100(1):107-13
pubmed: 25344526